CeCors Inc (CEOS) fair value: what the stock is really worth
As of Sep 25, 2026: fair value of CeCors Inc $0.00, price $0.00, upside +1.7%, quality 70 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch CeCors Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range $0.0023 – $0.1824 · fair‑value band $0.0041 – $0.0044 · the $0.0041 price screens below the $0.0042 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.
Follow CeCors in your weekly email
Every Wednesday you see whether CeCors is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Psykey, Inc. engages in the research, development, and commercialization of entheogenic, adaptogenic, and nootropic ingredients and formulations for its functional product lines. The company also engages in the development of technologies for the composition, bioavailability, and targeted delivery of entheogen-based therapeutics for the psychedelic market.
Show more
Psykey, Inc. engages in the research, development, and commercialization of entheogenic, adaptogenic, and nootropic ingredients and formulations for its functional product lines. The company also engages in the development of technologies for the composition, bioavailability, and targeted delivery of entheogen-based therapeutics for the psychedelic market. Its retail products include functional mushroom coffees and teas, oral supplements, and single serve drink mixes. The company was formerly known as CeCors, Inc. and changed its name to Psykey, Inc. in August 2021. The company was incorporated in 2002 and is based in Toronto, Canada.
Stock analysis
CeCors Inc (CEOS) currently trades at $0.0041, while our model-based Fair Value estimate is $0.0042, so the stock looks roughly fairly valued today (gap 1.7%).
Show more
Valuation
How firm this estimate is: it rests on 18 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: $0.0041 (bear) to $0.0044 (bull), the price of $0.0041 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 70/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
CeCors Inc reported revenue of $6.3M in FY2024 versus $1.5M in FY2016, a compound +19.2%/yr. Reported net income was $3.1M in FY2025.
Key figures
Market cap $1.7M · EPS (TTM) $−1.78 · Return on equity −726% · Return on assets (EBIT) −44.5% · Free cash flow $1.0M · Net cash $546K.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 53% below its 52-week high and 78% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −38% fair-value upside, at 2%, CEOS screens cheaper than that median.
Fair Value models
Bear $0.0041Fair Value $0.0042Bull $0.0044
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.69/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+1,397.7%
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.6%
’14
’15
’16
’22
’23
’24
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−47.3% (2018) → −5.1% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 185 stocks
Beats the industry median on 4/8 measures
A mixed picture versus its industry peers.
Valuation
Quality Score65 · Above median
Fair Value upside+1.7% · Above median
Profitability
Return on assets−179.7% · Bottom 25%
Net margin (TTM)−5.6% · Bottom 25%
Operating margin (TTM)0.0% · Bottom 25%
Growth and dividend
Revenue growth0.0% · Below median
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "CeCors Inc Fair Value". https://www.fairvalue-calculator.com/stock/CEOS
Frequently asked questions
Is CeCors Inc (CEOS) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of $0.0042 versus the last price from Sep 25, 2026 of $0.0041, about +2% upside (fairly valued).
What is the fair value of CEOS?
Our model-based fair value for CeCors Inc is $0.0042 (as of Sep 27, 2026), built from audited fundamentals. Last price (from Sep 25, 2026): $0.0041.
What is the quality score of CEOS?
CeCors Inc has a Quality Score of 70/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CeCors Inc (CEOS)?
Our model-based price target is the fair value of $0.0042 (as of Sep 27, 2026) from 18 valuation models. Cautious scenario $0.0041, optimistic scenario $0.0044. It is a calculation from audited fundamentals, not an analyst target.
What is the CeCors Inc stock forecast for 2026?
Our models put fair value at $0.0042, about +2% upside versus the last price from Sep 25, 2026 of $0.0041 (fairly valued). Cautious scenario $0.0041, optimistic scenario $0.0044. The calculation is refreshed regularly with new filings.
What is the intrinsic value of CeCors Inc (CEOS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CeCors Inc it is $0.0042 per share (as of Sep 27, 2026), against a price of $0.0041. It is the blended result of 18 valuation models (cash flow, earnings, asset, dividend).
Is CeCors Inc stock overvalued or undervalued in 2026?
As of Sep 27, 2026, CEOS trades below its calculated fair value: price $0.0041, fair value $0.0042, a gap of about +2% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CEOS?
No. The price is what the market pays today ($0.0041); the fair value is what the company's own numbers justify ($0.0042). For CeCors Inc the two are $0.0001 per share apart. That gap is exactly why we show both numbers side by side.
How much is CeCors Inc worth?
The market values CeCors Inc at about $1.7M (market capitalisation, as of Sep 27, 2026). Per share that is $0.0041; our models calculate a fair value of $0.0042 per share.
What do the bullish and bearish scenarios say about CEOS?
Our models span a range for CeCors Inc: cautious scenario $0.0041, base $0.0042, optimistic $0.0044 per share (as of Sep 27, 2026, price $0.0041). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is CEOS from its 52-week high?
CeCors Inc trades at $0.0041, about 53% below its 52-week high of $0.0087 and 78% above the low of $0.0023 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0042 is for.
Which stocks are comparable to CeCors Inc?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CeCors Inc stock attractive at the current price?
The data as of Sep 27, 2026: price $0.0041, calculated fair value $0.0042 (+2%), Quality Score 70/100, from 18 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CEOS calculated?
We run CeCors Inc through 18 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0042, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. CeCors Inc currently trades 2 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of CeCors Inc (CEOS)?
The latest price we hold is from Sep 25, 2026 and stands at $0.0041. Our model-based fair value is $0.0042, about +2% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CeCors Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The models converge in a tight band ($0.0041 to $0.0044), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of CeCors Inc
How large is the market capitalisation of CeCors Inc (CEOS)?
The market capitalisation of CeCors Inc is $1.7M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of CeCors Inc (CEOS)?
Earnings per share at CeCors Inc are $−1.78. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of CeCors Inc (CEOS)?
The return on equity (ROE) of CeCors Inc is −726% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CeCors Inc (CEOS)?
On an EBIT basis the return on assets of CeCors Inc is −44.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does CeCors Inc (CEOS) generate?
The free cash flow of CeCors Inc is $1.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does CeCors Inc (CEOS) hold?
CeCors Inc holds more cash than debt, $546K net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch CeCors Inc in the live analysis
One click puts CeCors Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 27, 2026